A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 8, 2020

Primary Completion Date

January 8, 2022

Study Completion Date

May 31, 2027

Conditions

Acute Lymphoblastic LeukemiaNon-hodgkin Lymphoma

Interventions

DRUG

CTA101

CTA101 UCAR-T cell injection by intravenous infusion

Trial Locations (1)

RECRUITING

The First Hospital of Zhejiang Medical Colleage Zhejiang University, Hangzhou

All Listed Sponsors

collaborator

Nanjing Bioheng Biotech Co., Ltd.

INDUSTRY

lead

He Huang

OTHER